12/17/2023 0 Comments Covid vaccine after effects moderna![]() ![]() ![]() 2 times the dose used for children 6 to 11 years of age (50 micrograms).The dose for people 12 years of age and older (100 micrograms) is: Dosage Primary seriesġ2 years and older (2 doses of 100 micrograms, 1 month apart)Ħ to 11 years (2 doses of 50 micrograms, 1 month apart)Ħ months to 5 years (2 doses of 25 micrograms, 1 month apart)ĭose volume depends on which series of the vaccine is being administered. The safety and effectiveness of the Moderna Spikevax® Monovalent COVID-19 vaccine (Omicron XBB 1.5) is based on studies of Spikevax® (Original, Original/Omicron BA.1 & XBB.1.5). 4/5) is based on studies of Spikevax ® Bivalent (Original/Omicron BA.1). The safety and effectiveness of the Moderna Spikevax ® Bivalent COVID-19 vaccine (Original/Omicron BA. This means that the booster is expected to offer protection against this variant. The Moderna Spikevax ® Bivalent COVID-19 vaccine (Original/Omicron BA.1) was shown to increase the immune response against the Omicron BA.1 variant. ![]() ![]() 51% effective in trial participants 6 to 23 months old.37% effective in trial participants 2 to 5 years old.as effective in trial participants 6 to 11 years old as in young adults (18 to 25 years old).100% effective in trial participants 12 to 17 years old.94.1% effective in protecting trial participants aged 18 and above against COVID-19.EffectivenessĬlinical trials showed that beginning 2 weeks after the second dose, the Moderna Spikevax ® COVID vaccine was: Its safety and effectiveness in people younger than 6 months has not yet been established. It may be given to people who have been previously vaccinated or who have not been previously vaccinated. The Moderna Spikevax® Monovalent COVID-19 vaccine (Omicron XBB.1.5 subvariant) is approved for people who are 6 months of age and older. Moderna Spikevax ® Monovalent COVID-19 vaccine (Omicron XBB.1.5 subvariant) Its safety and effectiveness in younger people has not yet been established. The Moderna Spikevax ® Bivalent COVID-19 vaccine (Original/Omicron BA.4/5) is approved as a booster for people who are 6 years of age and older. Moderna Spikevax ® Bivalent COVID-19 vaccine (Original/Omicron BA.4/5) The Moderna Spikevax ® Bivalent COVID-19 vaccine (Original/Omicron BA.1) is approved as a booster for people who are 6 years of age and older. Moderna Spikevax ® Bivalent COVID-19 vaccine (Original/Omicron BA.1) This vaccine is also approved as a booster for people 12 years of age and older. Its safety and effectiveness in people younger than 6 months have not yet been established. The Moderna Spikevax ® COVID-19 vaccine is approved for primary vaccination in people who are 6 months of age and older. Who the vaccines are approved for Moderna Spikevax ® COVID-19 vaccine Vaccine review, approval and monitoring.Primary series in individuals age 6 months and older, or as a booster dose in individuals age 12 years and older: Bivalent Original/Omicron BA.4/5 vaccine.As a booster dose in individuals age 6 years and older: ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |